Chao Lab

Nelson Chao, MD, Primary Investigator

Education

Fellow in Oncology, Medicine, Stanford University, 1985 - 1987
Medical Resident, Medicine, Stanford University, 1981 - 1984
M.D., Yale University, 1981

Research in the Chao Lab focuses on two broad areas, clinical hematopoietic stem cell and cord blood transplantation and in the laboratory studies related to graft vs. host disease and immune reconstitution. 

Lab Members

Nelson Chao, MD
Professor of Medicine
Donald D. and Elizabeth G. Cooke Cancer Research Professor
Professor in Immunology
Professor in Pathology
Member of the Duke Cancer Institute
Chief, Division of Cell Therapy in the Department of Medicine
Affiliate of the Regeneration Next Initiative

Megan Covington
Lab Manager, Sr. Lab Research Analyst
Yiqun Jiao
Sr. Research Associate
Amy Bush 
Lab Research Analyst I
David Williams 
Research Tech II
YuXian Huang
Visiting Scholar
Yujing "Penny" Zou
Grad Student
Shekeab Jauhari
House Staff, Fellow
Joanna Robles
House Staff, Fellow
Yaping Liu
Research Tech II
Excel Swann
Research Tech I

Current Studies

My research interests are in two broad areas, clinical hematopoietic stem cell and cord blood transplantation and in the laboratory studies related to graft vs. host disease and immune reconstitution. On the clinical side we are currently conducting approximately 50 different clinical protocols ranging from preparatory regimens, supportive care studies and disease specific protocols. Most of these clinical studies are centered around studies of the sources of stem cells and the methods to improve the long term outcome. There are exploratory protocols for novel therapies such as dendritic cell therapy for several malignancies, antiangiogenesis therapy, graft engineering to prevent graft-versus-host disease and antigen specific T cells or non specific NK cells to prevent relapse. Moreover a strong focus of the program is to develop cord-blood transplantation for adult patients with hematologic malignancies. The laboratory studies center on understanding the immunological events that occur with graft-vs-host disease and methods to prevent this disease. The current efforts focus on understanding murine reconstitution following transplantation, use of a peptide polymer to block MHC class II recognition of minor histocompatibility antigens, use of T cell engineering to prevent graft-versus-host disease at the same time preserving a graft-versus-malignancy effect.